Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene Therapies's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.41.
During the past 3 years, the average EBIT per Share Growth Rate was 50.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 42.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Taysha Gene Therapies's EBIT per Share or its related term are showing as below:
TSHA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 36.8 Med: 50.6 Max: 57.8
Current: 50.6
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Taysha Gene Therapies was 57.80% per year. The lowest was 36.80% per year. And the median was 50.60% per year.
TSHA's 3-Year EBIT Growth Rate is ranked better than 86.95% of 1172
companies
in the Biotechnology industry
Industry Median: 15.55
vs TSHA: 50.60
Taysha Gene Therapies (NAS:TSHA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Taysha Gene Therapies EBIT per Share Related Terms
Taysha Gene Therapies EBIT per Share Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a EBIT per Share of $-0.41 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taysha Gene Therapies and its competitors. According to the industry distribution chart, Taysha Gene Therapies ranks #153 out of 1172 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Taysha Gene Therapies' EBIT per Share too high?
Taysha Gene Therapies' current EBIT per Share is $-0.41. Based on the distribution chart, Taysha Gene Therapies ranks #153 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' EBIT per Share compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #153 out of 1172 companies for EBIT per Share. This places Taysha Gene Therapies in the top 13% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current EBIT per Share is $-0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $5.02 — trading 865.4% above its estimated fair value. The current EBIT per Share is $-0.41. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current EBIT per Share is $-0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 865.4% above its estimated GF Value™ of $0.52.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
EBIT per Share: $-0.41
GF Value™: $0.52 vs. price of $5.02 (865.4% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
